<DOC>
	<DOCNO>NCT02765841</DOCNO>
	<brief_summary>This Phase 3 single-arm , open-label , international , multi-center clinical trial evaluate efficacy safety lomitapide pediatric patient HoFH receive stable lipid-lowering therapy , include LDL apheresis . The study comprise 12-week Run-in Period , primary 24-week Efficacy Phase , follow 80-week Safety Phase .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Lomitapide Pediatric Patients With Homozygous Familial Hypercholesterolemia Stable Lipid-lowering Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>1 . Male female age ≥5 &lt; 18 year diagnose functional HoFH 2 . Patient must weigh least 15 kg 10th percentile BMI least 10th percentile height age gender base CDC growth chart 3 . Negative pregnancy test Screening study female child bear age 4 . Potentially sexually active female patient childbearing age must either sexually abstinent follow two acceptable method contraception 1 . Other form primary hyperlipoproteinemia secondary cause hypercholesterolemia ( e.g. , nephrotic syndrome , hypothyroidism ) . 2 . Abnormal liver function test Screening 3 . Moderate severe hepatic impairment active liver disease 4 . Serum creatine phosphokinase ( CPK ) level &gt; 2 × ULN . 5 . Chronic renal insufficiency 6 . History drug abuse within last 3 year habitual alcohol consumption 7 . New York Heart Association ( NYHA ) Class III IV congestive heart failure . 8 . Uncontrolled hypertension 9 . In judgment PI , precocious delay puberty endocrine disorder would affect growth 10 . History nonskin malignancy cancer occur within past 3 year 11 . History inflammatory bowel disease malabsorption syndrome history bowel resection , gastric bypass , weight loss surgical procedure . 12 . Use mipomersen within 6 month Screening . 13 . Any medical condition life expectancy predict less 5 year . 14 . Any patient unable avoid treatment strong moderate cytochrome P450 3A4 ( CYP3A4 ) inhibitor , drug contraindicate use lomitapide study . 15 . Participation interventional clinical study within 6 week statin therapy within 6 month unapproved therapy .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HoFH</keyword>
</DOC>